News

Investigators encourage further study of treatment and therapy methods for childhood IBD.

Patients hospitalized for STEMI achieved similar outcomes with rivaroxaban as warfarin after three months of follow-up in the RIVAWAR trial.

While the final treatment decision is with the physician, AI may have a role in assisting decision making in virtual urgent care.

Using CURE-CKD Registry data, the analysis showed relatively rapid-onset CKD was common in people with prediabetes, especially with hypertension or ASCVD.

Patients switching to tirzepatide had greater improvements in HBA1C and weight at week 40 in a phase 4 RCT.

In the first of 2 episodes spotlighting the meeting, hosts break down news and updates from the Advanced Technologies and Treatments for Diabetes meeting.

Study indicates pediatric uveitis can occur independent of autoimmune conditions and dupilumab use

In a new analysis at ACC.25, abelacimab reduced bleeding rates across the risk spectrum, with more benefits for those at higher bleeding risk.

These findings were the result of a new analysis of the inflammatory characteristics associated with the efficacy sustenance of biologic medications for psoriasis.

Our Q1 recap for hepatology spotlights regulatory updates, clinical trial data, 2 new guidance documents, and the anniversary of a historic FDA approval.

Cocoa flavanols can be helpful over a brief period, but after 2 years there is little benefit to risk of age-related macular degeneration.

Poon discussed a community health needs survey and how the “model minority” myth can impact care for Asian Americans.

These findings, while reassuring for JAK inhibitor prescription, nonetheless suggest that VTE-related recommendations for prescriptions should be maintained.

Q1 2025 allergy updates: FDA approved the first omalizumab biosimilar, and experts shared insights on peanut immunotherapy and food allergy treatments.

PBC patients with increased serum IgG levels at initial evaluation experienced faster disease progression and a greater probability of liver-related death.

Blood vessel inflammation directly influences incidence of age-related macular degeneration, epiretinal membrane, retinal vascular occlusion, and central serous chorioretinopathy

Marc Bonaca, MD, MPH, examines the benefit of semaglutide on functional outcomes in PAD from the STRIDE trial at ACC.25.

A recap of 10 clinical trials in cardiovascular care to know from the American College of Cardiology 2025 Scientific Sessions.

These findings indicate that lower ambient solar radiation is linked with more frequent systemic psoriasis therapy.

Aldeyra announces intention to resubmit NDA with new trial data in mid-year 2025.

The March 2025 month in review spotlights an RX Review about USMSTF guidance on bowel prep for colonoscopy, an FDA approval, and clinical trial updates.

The approval indicates Novartis's atrasentan (Vanrafia) for proteinuria reduction in primary IgA nephropathy.

The treatment for wet age-related macular degeneration failed to achieve its primary endpoint in both trials.

Blieden discusses long-term patient management in glaucoma, the importance of follow-up care, and the role of advocacy in ophthalmology.

Blieden describes recent advancements in the detection and treatment of narrow-angle glaucoma at TOA 2025.

McCulley examines the latest updates on GLP-1 receptor agonists relevant for ophthalmologists and patients with ophthalmic diseases at TOA 2025.

Participants with higher baseline eosinophil levels had the greatest responses and no participants experienced peaks of over 3000 eosinophils/µL.

Le examines the STRIDE, SOUL, and DapaTAVI trials presented at this year’s ACC Scientific Sessions.